Physician profile
Christopher J Evans
NPI 1063401263
$2,756.28
in general payments reported to CMS, 2019-2025
26 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what 75% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $90.96 · 2021: $357 · 2023: $124 · 2024: $753 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $463.23 | 2020-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $318.57 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.02 | 2019-2025 | Xifaxan |
| Abbvie INC. | $270.29 | 2025 | |
| Phathom Pharmaceuticals, INC. | $266.72 | 2023-2025 | Voquezna |
| Centinel Spine, LLC | $229.27 | 2021 | |
| Braintree Laboratories, INC. | $162.55 | 2020-2024 | Suflave |
| Ardelyx, INC. | $99.81 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $97.25 | 2024-2025 | Dupixent |
| Genzyme Corporation | $69.14 | 2024-2025 | |
| Lilly USA, LLC | $63.86 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $57.16 | 2023-2024 | Linzess |
| Pfizer INC. | $55.85 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $41.53 | 2024-2025 | Rebyota |
| Glaxosmithkline, LLC. | $39.38 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.17 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $30.14 | 2024 | |
| Merck Sharp & Dohme LLC | $28.20 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $25.06 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $21.51 | 2024 | Bylvay |
| Novo Nordisk INC | $20.00 | 2025 | Wegovy |
| Integra Lifesciences Corporation | $18.32 | 2023 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Davol INC. | $17.29 | 2023 | Echo Ps Positioning System |
| Sanofi Pasteur INC. | $16.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.72 | 2019 | |
| Boston Scientific Corporation | $14.17 | 2025 | Spaceoar System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.